Medetia SAS - TheRaCiL Partner

Medetia SAS

Focusing on paediatric ciliopathies, the French preclinical biotech Medetia develops innovative therapies for genetic diseases affecting kidney, retina, bone or cartilage. Medetia is poised to enter the clinic in 2025 with a well-tolerated small molecule to treat a rare retinal degenerative disease (LCA10). Thanks to its close relationship with two major research institutes in France, Inserm and Imagine, Medetia fosters its expertise in selecting other preclinical programs and transforming them into proprietary pipelines. In June 2023, Medetia also announced a strategic partnership with the international pharmaceutical group Ipsen to build some of these other pioneering drugs.

Researcher implicated in the project: Luis Briseno-Roa